CaTxGNN
Drug repurposing predictions for Health Canada approved medications using the TxGNN deep learning model.
Canada: what this site covers
This site publishes reports for 932 medicines listed in the registration data of Health Canada (Canada).
This site’s local data
| Item | Detail |
|---|---|
| Dataset | Drug Product Database (DPD) full data extracts: marketed (allfiles.zip), inactive (allfiles_ia.zip), dormant (allfiles_dr.zip) and approved (allfiles_ap.zip) products |
| Publisher | Health Canada |
| Download | https://www.canada.ca/content/dam/hc-sc/documents/services/drug-product-database/allfiles.zip (the other three files use the same address with _ia, _dr and _ap) |
| Product identifier | DIN |
| Updates | Automatic weekly download (every Monday); each DIN takes the DPD status (Marketed, Approved, Dormant, Cancelled…); a DIN missing from the new files keeps its previous status |
Details: Data Sources.
Reports by evidence level:
| Evidence level | Reports | Share |
|---|---|---|
| L1 | 12 | 1.3% |
| L2 | 41 | 4.4% |
| L3 | 36 | 3.9% |
| L4 | 62 | 6.7% |
| L5 | 729 | 78.2% |
| N/A | 52 | 5.6% |
73 predicted drug–disease pairs on this site appear on no other of the 30 TxGNN sites.
Highest evidence levels on this site
| Medicine | Evidence level |
|---|---|
| Acetylcysteine | L1 |
| Bendamustine | L1 |
| Bromfenac | L1 |
| Busulfan | L1 |
| Peginterferon Alfa-2A | L1 |
| Ribavirin | L1 |
| Clofarabine | L1 |
| Clomipramine | L1 |
| Doxorubicin | L1 |
| Ketorolac | L1 |
Medicines covered only by this site among the 30 TxGNN sites
| Medicine | Evidence level |
|---|---|
| Etafedrine | L3 |
| Butamben | L5 |
| Carbon Monoxide | L5 |
| Gramicidin D | L5 |
| Romidepsin | L5 |
| Butalbital | L5 |
| Monopotassium Phosphate | L5 |
| Methotrimeprazine | L5 |
| Thyroid Porcine | L5 |
| Anti-Inhibitor Coagulant Complex | L5 |
| Oxtriphylline | L5 |
| Dostarlimab | N/A |
| Efinaconazole | N/A |
| Lodoxamide | N/A |
| Piperonyl Butoxide | N/A |
Overview
This system analyzes Health Canada registered drugs to identify potential new therapeutic uses.
Statistics
| Metric | Value |
|---|---|
| Drug Reports | 932 |
| Mapped to DrugBank | 1,266 |
| Mapping Rate | 86.7% |
| Predicted New Indications (known uses excluded) | 5099 |
FHIR API
Access drug repurposing data via FHIR R4 API:
- Capability Statement: /fhir/metadata
- MedicationKnowledge: Drug information with DrugBank mappings
- ClinicalUseDefinition: Predicted therapeutic indications
Data Sources
- Drug Data: Health Canada Drug Product Database (DPD)
- Knowledge Graph: TxGNN
- Drug Identifiers: DrugBank
Disclaimer
This content is for research purposes only. Predictions are computational and have not been validated for clinical use. Always consult healthcare professionals before making any medical decisions.
Contact
- GitHub: yao-care/CaTxGNN
- Website: yao.care
About the Developer
This platform is developed and operated by 藥提醒科技有限公司 (yao.care). See the About page for the full company and methodology background.